# Abdominal Manifestations of Tuberous Sclerosis Complex

Muhammad Nabeel Akram, BS; Kai Xue, MD; Kaustubh G. Shiralkar, MD; Steven S. Chua, MD, PhD

# Introduction

Tuberous sclerosis complex (TSC) is a multisystem disorder that occurs 1 in 6000 live births.<sup>1</sup> The condition's manifestations are highly variable owing to penetrance, which determines the associated clinical presentation and outcome. Inherited in an autosomal-dominant fashion,<sup>2</sup> TSC is caused by mutations or loss of function in 2 tumor suppressor genes, tuberous sclerosis complexes 1 and 2 (TSC1, TSC2). These genes encode hamartin and tuberin, respectively, and together with a third subunit, *TBC1D7*, form a trimeric inhibitor complex that inhibits the mechanistic target of Rapamycin 1 (mTOR1) pathway, which is essential for normal growth.<sup>3</sup> The loss of *TSC1* or *TSC2* results in constitutive action of the mTOR1 pathway, which eventually leads to abnormal production of the multisystemic hamartomatous tumors seen in TSC.4

Seizures and intellectual disability are the 2 most common clinical presentations of TSC.<sup>1</sup> Dermatological findings are also common and present in 90% of cases.<sup>5</sup> Imaging can play an important role in identifying affected organs and complications. Most of these studies focus on the neurological impacts of TSC, but imaging for thoracoabdominal manifestations is equally important. A retrospective study of patients in a TSC registry demonstrated that thoracoabdominal manifestations occur more frequently in these patients than in the general population, supporting the need for detailed thoracoabdominal imaging to better define disease extent.<sup>6</sup> This review details the salient abdominal, pelvic, and chest manifestations of TSC to help facilitate and improve clinical diagnosis, treatment, and outcomes. The imaging features and complications of tuberous sclerosis lesions are summarized in Table 1.

Affiliations: Intercollegiate School of Engineering Medicine, College of Medicine, Texas A&M University, Houston, Texas (Akram). Regional Radiology, Cleveland Clinic, Cleveland, Ohio (Xue). University of Texas Health Science Center at Houston, Houston, Texas (Shiralkar, Chua).

**Disclosures:** The author has no conflicts of interest to disclose. No outside funding was received for the production of this original manuscript and no part of this article has been previously published elsewhere.

Published: April 1, 2025. https://doi.org/10.37549/AR-D-24-0074

@Anderson Publishing, Ltd. All rights reserved. Reproduction in whole or part without express written permission is strictly prohibited.

# Abdominal/Pelvic Manifestations

#### Angiomyolipomas

Renal angiomyolipoma (AMLs) are the most common abdominal manifestation of TSC<sup>1</sup>; they are considered a subset of the perivascular epithelioid cell (PEComa) group of mesenchymal tumors. PEComas have varying growth potential, ranging from benign/nonaggressive entities such as AMLs, through lesions of uncertain malignant potential, to frankly malignant sarcomas that demonstrate aggressive behavior and metastatic potential. <sup>16</sup> Malignant sarcomas will be discussed later in this review.

Renal AMLs are noted in 55-75% of individuals with TSC.<sup>13</sup> They are characterized by abnormal blood vessels, immature smooth muscle cells, and fat cells.<sup>17</sup> These entities are generally benign and asymptomatic, but large (typically >4 cm) AMLs and those with pseudoaneurysms >0.5 cm can predispose patients to an increased risk of hemorrhage.<sup>19</sup>

Renal AMLs are classified by subtypes based on their fat content (lipid-rich and lipid-poor), which can be distinguished with imaging.<sup>18</sup>

# **Table 1. Tuberous Sclerosis Complex Manifestations**

ORGAN	LESION	IMAGING FEATURES	COMPLICATIONS
Bone	Osseous lesions	Irregularly circumscribed and sclerotic appearance seen on CT.	Subperitoneal new bone deposition. <sup>1</sup> Usually asymptomatic. <sup>7</sup>
Heart	Rhabdomyoma	Variable signal intensities. Usually poorly enhancing.	Impaired ventricular function, valvular dysfunction, and outflow obstruction. <sup>8</sup>
Kidney	AML (part of PEComa)	Loss of signal in fat-saturated and opposed phase images if typical AML. Lipid-poor AML shows scant fat and variable soft tissues of muscle and vessels with heterogeneous enhancement. T2 hypointense to isointense.	Hemorrhage if size > 4 cm or pseudoaneurysm > 0.5 cm. <sup>1,9</sup> Progression of chronic renal disease, renal failure. <sup>1</sup>
Kidney	RCC	T2 hyperintense, heterogeneous to avid enhancement depending on subtype.	Hemorrhage, metastatic disease, venous thrombosis (bland and tumor), arterial involvement. <sup>10</sup>
Kidney	Cysts	Cysts of varying complexities; can be fluid density, proteinaceous/ hemorrhagic.	Chronic renal disease, renal failure, increased morbidity, cyst rupture.
Liver	AML (part of PEComa)	Similar to lipid-rich or lipid- poor AMLs in kidney. Lipid-poor hepatic AML can be confused with hepatocellular carcinomas and biopsy may be necessary to confirm.	Potential for rupture and hemorrhage <sup>11</sup> but much less frequent than renal AMLs.
Lung/retroperitoneum	LAM (part of PEComa)	Thin-walled cysts.	Recurrent pneumothoraces and chylous pleural effusions or ascites. <sup>12</sup>
Lung	ММРН	Ground glass nodules.	Usually stable disease.
Spleen	Hamartoma	Typically T1 hypointense, and T2 hyperintense. Small lesions may be isointense to the splenic parenchyma and seen as contour bulge.	Potential rupture, local mass effect. <sup>13</sup>
Pancreas	AML (part of PEComa)	Typical pancreatic AML similar to those seen in the kidneys and liver.	May alter pancreatic function. <sup>14</sup> Rare incidence.
Pancreas	Neuroendocrine tumor (rare)	Hypervascular and avidly enhancing. T2 hyperintense. Functional (hormone secreting) and nonfunctional tumors (non-hormone secreting).	Symptoms vary based on type of hormone secreted and if tumors are functional or not. <sup>15</sup>
Multiorgan	Malignant PEComas	Larger size, heterogeneous enhancement, with areas of necrosis, can metastasize to distant organs and bones.	Metastatic disease, increased morbidity and mortality.
cell; RCC, renal cell carcinoma.			

**Figure 1.** Lipid-rich angiomyolipoma (AML). AMLs typically contain macroscopic or bulk fat and can also contain microscopic or intravoxel fat. Intermediate lesions on T2 image (A, arrows) demonstrate loss of signal on T2-fat saturated image (B, arrows), indicating macroscopic fat. Phase imaging with T1 intermediate lesions in the kidneys (C, arrows) demonstrates loss of signal in the opposed phase image, indicating microscopic/intravoxel fat in AMLs (D, arrows). A large, left mid-to-superior renal pole echogenic lesion (E, asterisks and calipers) containing echogenic fat was found to be a ruptured AML with perinephric hematoma (##), whose thickness is delineated by the white double-headed arrow.



MRI can assist in identifying lipid-rich AMLs owing to the presence of macroscopic fat, seen as areas of decreased signal intensity in frequency-selected fat-saturated MRI sequences (Figure 1) and/or the presence of microscopic/intravoxel fat depicted as areas of decreased signal intensity and chemical shift type II artifact in opposed-phase MRI sequences (Figure 1).<sup>18</sup>On US, lipid-rich AMLs manifest as hyperechoic masses in the kidneys (Figure 1); cross-sectional imaging is often utilized to confirm this finding and exclude fat-containing renal cell carcinoma (RCC).<sup>1</sup>On CT, lipid-rich AMLs show macroscopic fatty lesions with attenuation < 10 HU.<sup>18</sup> In addition, heterogeneous

soft-tissue attenuation can also be seen on CT; contrast enhancement varies with vascularity and volume of soft tissue.<sup>18</sup>

Lipid-poor AMLs are more complex, with variable soft-tissue composition, including muscular or vascular components with limited or absent fat where no significant loss of signal intensity is seen in the fat-saturated or opposed MRI sequences (Figure 2).<sup>13</sup> They are typically T2 isointense to renal parenchyma and demonstrate variable contrast enhancement patterns on MRI or CT (Figure 3). Distinguishing lipid-poor AML from RCC can be challenging.<sup>1</sup> The former appears to enhance variably and does not show the wash-in

or wash-out characteristics typical of RCCs.<sup>10</sup> Additionally, RCCs may contain microscopic and, rarely, macroscopic fat, thought to result from osseous metaplasia.<sup>19</sup>

Although AMLs are usually benign, a rare subtype resulting from the transformation of a benign epithelioid AML via mutation can be malignant. These AMLs can present with locally invasive and aggressive features, as well as distant metastases known as multicentric AMLs of epithelioid morphology.<sup>13,20-22</sup> These lesions tend to be larger, appear more cellular, have internal necrosis and little fat, and demonstrate heterogeneous enhancement. Distant metastases may resemble RCCs on imaging, favoring a diagnosis of the **Figure 2.** Lipid-poor angiomyolipoma (AML). A T2 isointense renal lesion without significant loss of signal in the frequency fat-saturated sequence (T2 FS) suggesting the presence of macroscopic fat (A, arrow), and no loss of signal in the T1 opposed phase sequence suggesting microscopic/intravoxel fat (B, arrow) demonstrates mild arterial enhancement in the T1 fat-saturated, contrast-enhanced image (C, arrow). This lesion can be difficult to distinguish from a renal cell carcinoma.



**Figure 3.** Variable appearances of renal angiomyolipomas (AMLs) in tuberous sclerosis complex. Predominantly macroscopic fatcontaining AMLs show low CT attenuation with macroscopic fat <-10 HU (blue arrows). Lipid-poor AMLs with a more smooth muscle component are higher attenuation (yellow arrows). A more complex AML containing smooth muscle, vascular components, and tiny amounts of fat is seen in the left inferior renal pole (white arrow).



more aggressive epithelioid AML over the typical benign AML.<sup>14,23</sup>

In addition to the kidneys, AMLs can be found in other abdominal organs, though at a lower incidence. AMLs in the liver, pancreas, spleen, and/or gastrointestinal tract often coexist with renal AMLs.<sup>11,24,25</sup> A study of 187 patients with TSC found that only 28 (14%) had hepatic AMLs with renal AMLs<sup>26</sup>; a large registry study similarly found that 19% of patients with TSC had liver AMLs.<sup>6</sup> Hepatic AMLs can demonstrate a macroscopic fat component (Figure 4) but may also be confused with hepatocellular carcinoma if they are lipid-poor. Biopsy is frequently required for

Figure 4. Multiorgan angiomyolipomas (AMLs). Hepatic and pancreatic AMLs appear as regions of T2 hyperintensity in the liver and pancreas in T2. MR image (A, arrows) with loss of signal in the frequency selective fat-saturated T2 MR image (B, arrows).

**Figure 5.** Angiomyolipoma (AML) rupture. AMLs > 4 cm or containing pseudoaneurysms > 0.5 cm have an increased propensity to bleed. (A) Coronal CT reformation through large, ruptured AML with macroscopic fat (dotted white lines outlining lesion) in the right kidney (arrow) with resultant perinephric hematoma (\*\*) and internal hemorrhage (##). (B) Selective catheter arteriogram following AML rupture demonstrating multiple pseudoaneurysms (arrows), 2 with contrast extravasation indicating active hemorrhage (\*\*).



confirmation.<sup>24</sup> Hepatic AMLs are not typically stable lesions; they can grow and commonly demonstrate hypervascularity with macroscopic fat on contrast-enhanced imaging.<sup>13,27</sup> Unlike renal AMLs, hepatic AMLs

rarely rupture, with only 8 such cases reported in the literature.<sup>28</sup> These lesions tended to be large, with an average diameter of 8 cm. Hepatic AMLs > 5 cm with more aggressive epithelioid morphology on biopsy have been shown to benefit from surgical resection.<sup>29</sup>

AMLs can also occur in the pancreas, where they manifest as macroscopic fatty lesions (Figure 4) and may affect pancreatic function.<sup>11</sup> **Figure 6.** Renal cysts and renal cell carcinoma. Coronal CT reformation in a patient with tuberous sclerosis complex, end-stage renal disease, and associated polycystic kidney disease was found to have an avidly arterially enhancing right renal mass diagnosed as renal cell carcinoma (\*\*) on a background of multiple renal cysts (##).



These AMLs are extremely rare, with only a few cases reported,<sup>11,30</sup> and are among 1% of pancreatic tumors of mesenchymal origin.<sup>31</sup> Heywood et al reported a case of a pancreatic AML with hemorrhage that appeared as a heterogeneous lesion on US and a cystic lesion with an irregular, thickened wall on CT.<sup>11</sup>

As alluded to earlier, large renal AMLs (>4 cm, Figure 5) or those that possess pseudoaneurysms > 0.5 cm can increase the risk for hemorrhage, <sup>1,9,32</sup> which may be fatal if not detected and promptly treated. Manifestations of shock and hypovolemia in this setting are termed Wunderlich syndrome, <sup>32,33</sup> which, after status epilepticus, is the second-most frequent complication among patients with TSC. <sup>13</sup> Prophylactic embolization or resection can help reduce mortality.<sup>1</sup>

# **Renal Cysts**

Renal cysts and polycystic kidney disease are common in individuals with TSC (Figure 6)<sup>17,34,35</sup>; both

were found in approximately 72% of patients in a large registry study.<sup>6</sup> Renal cysts are typically asymptomatic but can lead to polycystic kidney disease and the development of hypertension and/or renal failure in the setting of TSC.<sup>17,34,35</sup>

# **Renal Cell Carcinoma**

Renal cell carcinoma is another manifestation that can occur in patients with TSC (Figure 6).<sup>1,8,13,36-39</sup> These tumors tend to occur in young adults and can be of any subtype (clear cell, papillary, or chromophobe), the most common being clear cell.<sup>17,38,40</sup> This finding underscores the importance of continuous imaging surveillance in patients with renal lesions, preferably with multiphasic MRI owing to its superior soft-tissue resolution, ability to perform chemical shift sequences and fat saturation, and lack of ionizing radiation. Multiphasic MRI should be performed every 1-3 years as part of a thoracoabdominal imaging

protocol for TSC.<sup>41</sup> Where MRI is contraindicated, multiphasic CT with a renal mass-oriented protocol may be helpful.

#### Hamartomas

Splenic hamartomas may be encountered in patients with TSC, albeit rarely.<sup>13</sup> US imaging typically demonstrates solid masses hyperechoic to their surroundings along with increased blood flow on Doppler imaging.<sup>13</sup> Other common sonographic findings are calcifications and cystic changes. On MRI, splenic hamartomas are usually T1 hypointense and T2 hyperintense to the splenic parenchyma. They can also be hypervascular and diffusely contrast-enhancing, particularly on early postcontrast imaging.13

# Cardiothoracic and Musculoskeletal Manifestations

### Lymphangioleiomyomatosis

One pulmonary manifestation of tuberous sclerosis is lymphangioleiomyomatosis (LAM),<sup>42-44</sup> which is also a member of the PEComa group of tumors.<sup>16</sup> LAM manifests as an abnormal proliferation of smooth muscle cells in the lymphatic system accompanied by cystic changes within the lung parenchyma. This can result in lung parenchymal destruction, dyspnea, and ultimately require lung transplantation.<sup>12,45</sup> There are 2 forms of LAM: one associated with TSC (TSC/LAM) and a more common sporadic form, both with female predominance.46 The TSC/LAM form is the more aggressive of the 2, presents with more severe disease, and is seen in 26-39% of patients with TSC.47 One complication of LAM is chylous pleural effusion formation, which disrupts the lymphatic system in the chest.<sup>1</sup> On CT imaging, LAM will manifest as multiple

**Figure 7.** Other manifestations of tuberous sclerosis complex (TSC). (A) Axial CT showing pulmonary lymphangioleiomyomatosis characterized by thin-walled cysts (white arrows) and micronodular pneumocyte hyperplasia manifested by ground glass nodules (yellow arrows) in a patient with TSC. (B) Coronal T2 MRI showing how lymphangioleiomyomas can develop in the retroperitoneal region as in this T2 hyperintense signal mass (##, arrows) in the left retroperitoneal region abutting the left kidney. (C) T1 fat-saturated postcontrast axial image of the heart demonstrating a nonenhancing rhabdomyoma (white arrow) in the right ventricle. (D). Dixon fat-only MRI sequence with a tumor containing macroscopic fat at the ventricular septum (arrow) TSC appearing as a hyperintense lesion consistent with a cardiac angiomyolipoma. (E) Sagittal CT reformation of the spine in a patient with TSC and multiple sclerotic bony lesions in the vertebral bodies (arrows).



**Figure 8.** Aggressive malignant perivascular epithelioid cell tumor (PEComa). T1-fat saturated postcontrast MRI demonstrates an expansile and aggressive left pelvic lesion (arrows) eroding the left iliac crest and invading the adjacent left gluteal (G) and left iliopsoas (I) muscles. The tumor is heterogeneously enhanced with areas of internal necrosis (\*) and was proven to be a recurrent malignant PEComa in a patient with a previous pulmonary PEComa that was treated and subsequently resected. A satellite lesion in the left iliac bone is also seen (##).



thin-walled cysts (Figure 7).<sup>44,48</sup> Reticular opacities may also be seen, which may indicate that edema is obstructing vessels.<sup>17</sup> Pneumothorax is another complication of LAM that may require intervention.<sup>1,17</sup>

Lymphangioleiomyomas can also be seen in the retroperitoneal region as T2 hyperintense cystic dilatations involving the lymphatic system and lymphadenopathy.<sup>49</sup> Complications include mass effect on retroperitoneal organs, chylous ascites, cyst rupture, and abdominal pain.<sup>7,50</sup>

# Micronodular Pneumocyte Hyperplasia

A third, less common, pulmonary manifestation of TSC is multifocal micronodular pneumocyte hyperplasia (MMPH), seen in approximately 18% of patients in a registry study.<sup>6</sup> The condition is characterized by a well-demarcated nodular proliferation scattered randomly throughout the lungs and manifesting as ground glass nodules on CT (Figure 7).<sup>49,51</sup> MMPH can occur concomitantly with or independently from LAM.

#### **Cardiac Manifestations**

Cardiac-related conditions are prominent in TSC.<sup>1,38,43</sup> Approximately 70% of children with cardiac rhabdomyomas have TSC.<sup>1</sup> Rhabdomyomas are benign, striated muscle tumors accompanied by "spider cells."<sup>17,42</sup> US typically depicts a well-defined hyperechoic mass along the intraventricular septum.<sup>13</sup> On MRI, rhabdomyomas show little to no contrast enhancement (Figure 7).

Although less common than rhabdomyomas, AMLs can also be intracardiac and are usually located at the apex or in the ventricular wall.<sup>50</sup> Noncontrast CT may show fat attenuation (<10 HU) in these lesions. Cardiac AMLs show macroscopic fat and are hyperintense on Dixon fat-only sequences (Figure 7).

#### **Osseous Manifestations**

Osseous findings of TSC include sclerotic lesions, bone cysts, and periosteal new bone formation, the latter occurring particularly in the metacarpal areas.<sup>52</sup> Sclerotic lesions can be identified in the ribs, vertebral posterior elements, and along the iliac side of the sacroiliac joints (Figure 7).<sup>52</sup> Rarely, TSC can cause macrodactyly.<sup>53</sup> As nonspecific findings, these are nondiagnostic of TSC.<sup>52</sup>

#### PEComas

PEComas are rare mesenchymal neoplasms that can be benign or malignant entities with variable biologic features and oncologic outcomes.54,55 Both types of lesions are associated with alterations predominantly of the TSC2 gene, while a distinct subset of malignant PEComas can harbor other mutations.<sup>55,56</sup> Benign lesions of the PEComa family include AML and LAM, while more aggressive entities termed malignant PEComas/sarcomas demonstrate a higher mitotic rate and growth potential. Malignant tumors can be found in patients with TSC and sporadically in patients without TSC.13,15,16

On imaging, malignant PEComas can be differentiated from their benign counterparts based on their typically larger size (>5 cm), infiltrative growth, necrosis, and/or osseous destruction (Figure 8). They can also invade blood vessels and metastasize to other organs and tissues such as the liver, lungs, and bones.<sup>13,15,57</sup> Owing to their deregulated growth, malignant PEComas can demonstrate fluorodeoxyglucose avidity on PET/CT.58 Multiphasic MRI and CT and PET/CT can all be useful in screening for malignant PEComas and assessing treatment efficacy with serial imaging studies.

Patients with TSC with AMLs and non-AML PEComas, as well as some with gastrointestinal polyps, have an overall increased risk for developing

malignancies. AMLs and non-AML PEComas are also associated with pancreatic neuroendocrine tumors,<sup>59</sup> further underscoring the need for imaging surveillance.

#### Conclusion

Tuberous sclerosis complexhas a wide range of manifestations in the abdomen, pelvic, and chest. Renal AMLs are most common, but they can also occur in the liver, pancreas, and spleen. Thoracic manifestations include LAM, MMPH, and cardiac rhabdomyomas and AMLs. Recognizing these lesions can facilitate accurate diagnosis and optimal treatment planning in patients with TSC.

#### References

1) Manoukian SB, Kowal DJ. Comprehensive imaging manifestations of tuberous sclerosis. *AJR Am J Roentgenol.* 2015;204(5):933-943. doi:10.2214/AJR. 13.12235

2) Rosengren T, Nanhoe S, de Almeida LGD, et al. Mutational analysis of TSC1 and TSC2 in danish patients with tuberous sclerosis complex. *Sci Rep.* 2020;10(1):9909. doi:10. 1038/s41598-020-66588-4

 Dibble CC, Elis W, Menon S, et al. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. *Mol Cell*. 2012;47(4):535-546. doi:10.1016/j.molcel.2012.
06.009

4) Orlova KA, Crino PB. The tuberous sclerosis complex. *Ann N Y Acad Sci.* 2010;1184:87-105. doi:10.1111/j.1749-6632. 2009.05117.x

5) Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. *Lancet*. 2008;372(9639):657-668. doi:10.1016/S0140-6736(08)61279-9

6) Ritter DM, Fessler BK, Ebrahimi-Fakhari D, et al. Prevalence of thoracoabdominal imaging findings in tuberous sclerosis complex. *Orphanet J Rare Dis.* 2022;17(1):124. doi:10.1186/s13023-022-02277-x

7) Elia D, Torre O, Cassandro R, Caminati A, Harari S. Ultra-rare cystic disease. *Eur Respir Rev.* 2020;29(157):190163. doi:10.1183/ 16000617.0163-2019 8) Khallouk A, Ahallal Y, Doublali M, et al. Concurrent bilateral renal angiomyolipoma and renal cell carcinoma in a patient with tuberous sclerosis complex. *Rev Urol.* 2009;11(4):216-218.

9) Yamakado K, Tanaka N, Nakagawa T, et al. Renal angiomyolipoma: relationships between tumor size, aneurysm formation, and rupture. *Radiology*. 2002;225(1):78-82. doi:10.1148/radiol.2251011477

10) Xie P, Yang Z, Yuan Z. Lipid-poor renal angiomyolipoma: differentiation from clear cell renal cell carcinoma using wash-in and washout characteristics on contrast-enhanced computed tomography. *Oncol Lett.* 2016;11(3):2327-2331. doi:10.3892/ ol.2016.4214

11) Heywood G, Smyrk TC, Donohue JH. Primary angiomyolipoma of the pancreas. *Pancreas*. 2004;28(4):443-445. doi: 10.1097/00006676-200405000-00014

12) Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. *N Engl J Med.* 1996;335(17):1275-1280. doi:10.1056/ NEJM199610243351704

13) Wang MX, Segaran N, Bhalla S, et al. Tuberous sclerosis: current update. *Radiographics*. 2021;41(7):1992-2010. doi:10. 1148/rg.2021210103

14) Bharwani N, Christmas TJ, Jameson C, Moat N, Sohaib SA. Epithelioid angiomyolipoma: imaging appearances. *Br J Radiol*. 2009;82(984):e249-52. doi:10.1259/bjr/ 27259024

15) Sobiborowicz A, Czarnecka AM, Szumera-Ciećkiewicz A, Rutkowski P, Świtaj T. Diagnosis and treatment of malignant pecoma tumours. *Oncol Clin Pract*. 2020;16(1):22-33. doi:10.5603/OCP.2020.0003

16) Folpe AL, Mentzel T, Lehr H-A, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. *Am J Surg Pathol.* 2005;29(12):1558-1575. doi:10.1097/01. pas.0000173232.22117.37

17) Umeoka S, Koyama T, Miki Y, et al. Pictorial review of tuberous sclerosis in various organs. *Radiographics*. 2008;28(7):e32. doi:10.1148/rg.e32

18) Pereira JM, Sirlin CB, Pinto PS, Casola G. CT and MR imaging of extrahepatic fatty masses of the abdomen and pelvis: techniques, diagnosis, differential diagnosis, and pitfalls. *Radiographics*. 2005;25(1):69-85. doi:10.1148/rg.251045074

19) Richmond L, Atri M, Sherman C, Sharir S. Renal cell carcinoma containing macroscopic fat on CT mimics an angiomyolipoma due to bone metaplasia without macroscopic calcification. *Br J Radiol.* 2010;83(992):e179-81. doi:10.1259/bjr/ 46452134 20) Pea M, Bonetti F, Martignoni G, et al. Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma. *Am J Surg Pathol.* 1998;22(2):180-187. doi:10.1097/00000478-199802000-00005

21) Lin WC, Wang JH, Wei CJ, Pan CC, Chang CY. Malignant renal epithelioid angiomyolipoma with aggressive behavior and distant metastasis. *J Chin Med Assoc*. 2003;66(5):303-306.

22) Lai H-Y, Chen C-K, Lee Y-H, et al. Multicentric aggressive angiomyolipomas: a rare form of pecomas. *AJR Am J Roentgenol*. 2006;186(3):837-840. doi:10.2214/AJR.04.1639

23) Thiravit S, Teerasamit W, Thiravit P. The different faces of renal angiomyolipomas on radiologic imaging: a pictorial review. *Br J Radiol.* 2018;91(1084):20170533. doi:10.1259/bjr.20170533

24) Tsui WM, Colombari R, Portmann BC, et al. Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants. *Am J Surg Pathol.* 1999;23(1):34-48. doi:10. 1097/00000478-199901000-00004

25) Thipphavong S, Duigenan S, Schindera ST, Gee MS, Philips S. Nonneoplastic, benign, and malignant splenic diseases: cross-sectional imaging findings and rare disease entities. *AJR Am J Roentgenol.* 2014;203(2):315-322. doi:10.2214/ AJR.13.11777

26) Jóźwiak S, Sadowski K, Borkowska J, et al. Liver angiomyolipomas in tuberous sclerosis complex-their incidence and course. *Pediatr Neurol.* 2018;78:20-26. doi:10. 1016/j.pediatrneurol.2017.09.012

27) Ding G-H, Liu Y, Wu M-C, et al. Diagnosis and treatment of hepatic angiomyolipoma. *J Surg Oncol.* 2011;103(8):807-812. doi:10.1002/ jso.21814

28) Kim SH, Kang TW, Lim K, et al. A case of ruptured hepatic angiomyolipoma in a young male. *Clin Mol Hepatol.* 2017;23(2):179-183. doi:10.3350/cmh.2016.0027

29) Calame P, Tyrode G, Weil Verhoeven D, et al. Clinical characteristics and outcomes of patients with hepatic angiomyolipoma: a literature review. *World J Gastroenterol.* 2021;27(19):2299-2311. doi:10.3748/wjg. v27.i19.2299

30) Kim JY, Song JS, Park H, et al. Primary mesenchymal tumors of the pancreas: single-center experience over 16 years. *Pancreas*. 2014;43(6):959-968. doi:10. 1097/MPA.00000000000130

31) Kim HH, Park DH. Imaging findings of primary angiomyolipoma of the pancreas: a case report. *J Korean Soc Radiol*. 2017;77(1):9. doi:10.3348/jksr.2017.77.1.9

32) Zhang JQ, Fielding JR, Zou KH. Etiology of spontaneous perirenal hemorrhage: a meta-analysis. *J Urol.* 2002;167(4):1593-1596. doi:10.1097/00005392-200204000-00006

33) Moratalla MB. Wunderlich's syndrome due to spontaneous rupture of large bilateral angiomyolipomas. *Emerg Med J.* 2009;26(1):72. doi:10.1136/emj.2008.062091

34) Sampson JR, Maheshwar MM, Aspinwall R, et al. Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene. *Am J Hum Genet*. 1997;61(4):843-851. doi:10.1086/514888

35) Dixon BP, Hulbert JC, Bissler JJ. Tuberous sclerosis complex renal disease. *Nephron Exp Nephrol.* 2011;138(3):e15-e20. doi:10.1016/S0022-5347(17)43234-4

36) Bernstein J, Robbins TO. Renal involvement in tuberous sclerosis. *Ann N Y Acad Sci.* 1991;615:36-49. doi:10.1111/j.1749-6632.1991.tb37746.x

37) Bjornsson J, Short MP, Kwiatkowski DJ, Henske EP. Tuberous sclerosis-associated renal cell carcinoma. clinical, pathological, and genetic features. *Am J Pathol.* 1996;149(4):1201-1208.

38) Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. *N Engl J Med.* 2006;355(13):1345-1356. doi:10.1056/ NEJMra055323

39) Stillwell TJ, Gomez MR, Kelalis PP. Renal lesions in tuberous sclerosis. J Urol. 1987;138(3):477-481. doi:10.1016/s0022-5347(17)43234-4

40) von Ranke FM, Faria IM, Zanetti G, et al. Imaging of tuberous sclerosis complex: a pictorial review. *Radiol Bras*. 2017;50(1):48-54. doi:10.1590/0100-3984.2016. 0020

41) Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. *Pediatr Neurol*. 2021;123:50-66. doi:10. 1016/j.pediatrneurol.2021.07.011

42) Hinton RB, Prakash A, Romp RL, et al. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the international tuberous sclerosis consensus group. *J Am Heart Assoc.* 2014;3(6):e001493. doi:10.1161/JAHA. 114.001493 43) Gupta N, Henske EP. Pulmonary manifestations in tuberous sclerosis complex. *Am J Med Genet C Semin Med Genet*. 2018;178(3):326-337. doi:10.1002/ajmg. c.31638

44) Harari S, Torre O, Moss J. Lymphangioleiomyomatosis: what do we know and what are we looking for? *Eur Respir Rev.* 2011;20(119):34-44. doi:10.1183/ 09059180.00011010

45) McCarthy C, Gupta N, Johnson SR, Yu JJ, McCormack FX. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. *Lancet Respir Med.* 2021;9(11):1313-1327. doi:10.1016/S2213-2600(21)00228-9

46) Avila NA, Dwyer AJ, Rabel A, Moss J. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. *Radiology*. 2007;242(1):277-285. doi: 10.1148/radiol.2421051767

47) Costello LC, Hartman TE, Ryu JH. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. *Mayo Clin Proc*. 2000;75(6):591-594. doi:10.4065/75.6.591

48) Johnson SR, Cordier JF, Lazor R, et al. European respiratory society guidelines for the diagnosis and management of lymphangioleiomyomatosis. *Eur Respir J.* 2010;35(1):14-26. doi:10.1183/ 09031936.00076209

49) Rebaine Y, Nasser M, Girerd B, Leroux C, Cottin V. Tuberous sclerosis complex for the pulmonologist. *Eur Respir Rev.* 2021;30(161):200348. doi:10.1183/ 16000617.0348-2020

50) Lenfant C, Dragean CA. Retroperitoneal lympathic malformations as first presentation of lymphangioleiomyomatosis. *J Belg Soc Radiol*. 2021;105(1):32. doi:10.5334/ jbsr.2468

51) Pannu BS, Apala DR, Kotecha A, Boland JM, Iyer VN. Multifocal Micronodular Pneumocyte Hyperplasia (MMPH) in a patient with tuberous sclerosis-evidence for long term stability. *Respir Med Case Rep.* 2017;20:113-115. doi:10.1016/j.rmcr.2017. 01.010

52) Boronat S, Barber I, Thiele EA. Sclerotic bone lesions in tuberous sclerosis complex: a genotype-phenotype study. *Am J Med Genet A*. 2017;173(7):1891-1895. doi:10.1002/ajmg.a. 38260 53) Tung HE, Shih SL. Tuberous sclerosis with rare presentation of macrodactyly. *Pediatr Radiol.* 2009;39(8):878. doi:10.1007/ s00247-009-1195-8

54) Thway K, Fisher C. PEComa: morphology and genetics of a complex tumor family. *Ann Diagn Pathol*. 2015;19(5):359-368. doi:10.1016/ j.anndiagpath.2015.06.003

55) Gadducci A, Zannoni GF. Perivascular epithelioid cell tumors (pecoma) of the female genital tract: a challenging question for gynaecologic oncologist and pathologist. *Gynecol Oncol Rep.* 2020;33:100603. doi:10. 1016/j.gore.2020.100603

56) Agaram NP, Sung Y-S, Zhang L, et al. Dichotomy of genetic abnormalities in pecomas with therapeutic implications. *Am J Surg Pathol*. 2015;39(6):813-825. doi:10.1097/ PAS.00000000000389

57) Benson C, Vitfell-Rasmussen J, Maruzzo M, et al. A retrospective study of patients with malignant pecoma receiving treatment with sirolimus or temsirolimus: the royal marsden hospital experience. *Anticancer Res.* 2014;34(7):3663-3668.

58) Sun L, Sun X, Li Y, Xing L. The role of (18)F-FDG PET/CT imaging in patient with malignant pecoma treated with mtor inhibitor. *Onco Targets Ther.* 2015;8:1967-1970. doi:10.2147/OTT.S85444

59) Mowrey K, Northrup H, Rougeau P, et al. Frequency, progression, and current management: report of 16 new cases of nonfunctional pancreatic neuroendocrine tumors in tuberous sclerosis complex and comparison with previous reports. *Front Neurol.* 2021;12:627672. doi:10.3389/ fneur.2021.627672